{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:56:04Z","timestamp":1790661364508,"version":"4.1.0"},"reference-count":14,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Invasive fungal infections are important causes of morbidity and attributable mortality in neutropenic patients with hematological malignancies, myelodysplasia, and aplastic anemia. Successful risk-based strategies can be implemented for prophylaxis, empirical therapy, and preemptive therapy for the prevention and early treatment of invasive fungal infections in neutropenic hosts. The use of echinocandins for invasive candidiasis and voriconazole for invasive aspergillosis has significantly improved outcome. Recent studies demonstrate, however, that resistant fungal pathogens may emerge during the course of these antifungal interventions. Although triazole-resistant Candida spp. have been well described as causes of breakthrough candidemia, other organisms now pose a similar threat. Such organisms include echinocandin-resistant Candida glabrata and Candida parapsilosis species complex. The Mucorales, Fusarium spp., and Scedosporium spp. may emerge in the setting of voriconazole prophylaxis. The challenges of these emerging pathogens underscore the need for the development of new antifungal agents and strategies.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.423","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T10:51:13Z","timestamp":1386327073000},"page":"423-427","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":61,"title":["Treatment of fungal disease in the setting of neutropenia"],"prefix":"10.1182","volume":"2013","author":[{"given":"Thomas J.","family":"Walsh","sequence":"first","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program,"},{"name":"Department of Pediatrics, and"},{"name":"Department of Microbiology & Immunology, Weill Cornell Medical Center of Cornell University, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria N.","family":"Gamaletsou","sequence":"additional","affiliation":[{"name":"Laikon General Hospital and Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111703002818300_B1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.seminhematol.2009.03.002","article-title":"Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes","volume":"46","author":"Bow","year":"2009","journal-title":"Semin Hematol"},{"key":"2019111703002818300_B2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/cncr.20890","article-title":"Perspectives for the management of febrile neutropenic patients with cancer in the 21st century","volume":"103","author":"Sipsas","year":"2005","journal-title":"Cancer"},{"key":"2019111703002818300_B3","article-title":"A prospective, cohort, multicenter study of candidemia in hospitalized adult patients with hematological malignancies","author":"Gamaletsou","journal-title":"Clin Microb Infect"},{"key":"2019111703002818300_B4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019111703002818300_B5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12281-010-0044-4","article-title":"Invasive candidiasis in the neutropenic host","volume":"5","author":"Gamaletsou","year":"2011","journal-title":"Curr Fungal Infect Rep"},{"key":"2019111703002818300_B6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/653935","article-title":"Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials","volume":"51","author":"Nucci","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2019111703002818300_B7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2141.2007.06906.x","article-title":"Considerations in the approach to invasive fungal infection in patients with haematological malignancies","volume":"140","author":"Bow","year":"2008","journal-title":"Br J Haematol"},{"key":"2019111703002818300_B8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2019111703002818300_B9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1470-9465.2004.00839.x","article-title":"Infections due to emerging and uncommon medically important fungal pathogens","volume":"10","author":"Walsh","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"2019111703002818300_B10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11908-012-0272-6","article-title":"Rhino-orbital-cerebral mucormycosis","volume":"14","author":"Gamaletsou","year":"2012","journal-title":"Curr Infect Dis Rep"},{"key":"2019111703002818300_B11","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019111703002818300_B12","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/cid\/cir868","article-title":"Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)","volume":"54","author":"Walsh","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019111703002818300_B13","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/cid\/cir885","article-title":"Combination therapy for mucormycosis: why, what, and how?","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019111703002818300_B14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1128\/CMR.00039-07","article-title":"Infections caused by Scedosporium spp","volume":"21","author":"Cortez","year":"2008","journal-title":"Clin Microbiol Rev"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/423\/1249264\/bep00113000423.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/423\/1249264\/bep00113000423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:00:37Z","timestamp":1573959637000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/423\/20702\/Treatment-of-fungal-disease-in-the-setting-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.423","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}